Günal Ali Ihsan, Celiker Huseyin, Ustundag Bilal, Akpolat Nusret, Dogukan Ayhan, Akcicek Fehmi
Department of Nephrology, Firat University School of Medicine, 23200 Elazig, Turkey.
J Nephrol. 2003 Mar-Apr;16(2):225-30.
Chronic peritoneal dialysis (PD) can result in several peritoneal alterations of varying degree, which lead to progressive reduction in dialytic efficacy. Although its pathogenesis has not been clarified yet, it has been proposed that high glucose induced oxidative stress generation within the peritoneal membrane plays an important role in leading to membrane alterations. The aim of this study was to investigate the effect of oxidative stress inhibition on peritoneal alterations induced by hypertonic PD solutions in rats.
The rats were divided into three groups receiving no treatment (the control group), hypertonic PD solution intraperitoneally (ip) only (the hypertonic dextrose group) and hypertonic PD solution ip plus trimetazidine (TMZ) orally (TMZ group). After 4 weeks, a one-hour peritoneal equilibration test (PET) was performed. Dialysate-to-plasma urea ratio (D/P urea), glucose reabsorption (D(1)/D(0) glucose), ultrafiltration volume (UF) and the level of dialysate protein were determined. The levels of malondialdehyde (MDA), vascular endothelial growth factor (VEGF) and the activity of glutathione peroxidase (GPx) were investigated in the peritoneal tissue lysates. The peritoneal membrane was evaluated histologically by light microscopy.
Compared to the control group, peritoneal function tests (UF: 3.6 +/- 0.4 vs. 1.2 +/- 0.6 mL, D/P urea: 0.57 +/- 0.03 vs. 0.76 +/- 0.04, D(1)/D(0) glucose: 0.46 +/- 0.02 vs. 0.33 +/- 0.05) and morphology (thickness: 4.4 +/- 0.5 vs. 61 +/- 14 micro m and neovascularisation: 0.2 +/- 0.4 vs 2.4 +/- 0.8 number/field) were dramatically altered in the hypertonic PD solution-treated rats. Likewise, higher levels of VEGF, MDA and decreased activity of GPx were determined in the hypertonic PD solution-treated rats. Although peritoneal thickness (37 +/- 17 micro m) was not completely decreased, peritoneal functions were protected in the TMZ group (UF: 4.0 +/- 0.4 mL, D/P urea: 0.62 +/- 0.06, D(1)/D(0) glucose: 0.43 +/- 0.02). In the TMZ group, MDA and VEGF levels and neoangiogenesis were significantly less than those of the hypertonic dextrose group. In addition, GPx activity significantly increased in the TMZ group.
These data demonstrated that not only generating oxidative stress but also attenuating antioxidative system and high glucose concentration can cause structural and functional alterations within the peritoneal membrane. TMZ can preserve these alterations by inhibiting the oxidative stress within the peritoneal membrane.
慢性腹膜透析(PD)可导致不同程度的多种腹膜改变,进而导致透析效能逐渐降低。尽管其发病机制尚未阐明,但有人提出高糖诱导腹膜内氧化应激的产生在导致膜改变中起重要作用。本研究的目的是探讨氧化应激抑制对高渗PD溶液诱导的大鼠腹膜改变的影响。
将大鼠分为三组,分别为不治疗组(对照组)、仅腹腔内注射(ip)高渗PD溶液组(高渗葡萄糖组)和腹腔内注射高渗PD溶液加口服曲美他嗪(TMZ)组(TMZ组)。4周后,进行1小时的腹膜平衡试验(PET)。测定透析液与血浆尿素比值(D/P尿素)、葡萄糖重吸收(D(1)/D(0)葡萄糖)、超滤量(UF)和透析液蛋白水平。检测腹膜组织裂解物中丙二醛(MDA)、血管内皮生长因子(VEGF)水平及谷胱甘肽过氧化物酶(GPx)活性。通过光学显微镜对腹膜进行组织学评估。
与对照组相比,高渗PD溶液处理的大鼠腹膜功能测试(UF:3.6±0.4 vs. 1.2±0.6 mL,D/P尿素:0.57±0.03 vs. 0.76±0.04,D(1)/D(0)葡萄糖:0.46±0.02 vs. 0.33±0.05)和形态(厚度:4.4±0.5 vs. 61±14μm,新生血管形成:0.2±0.4 vs 2.4±0.8个/视野)发生了显著改变。同样,高渗PD溶液处理的大鼠中VEGF、MDA水平升高,GPx活性降低。尽管TMZ组腹膜厚度(37±17μm)未完全降低,但腹膜功能得到了保护(UF:4.0±0.4 mL,D/P尿素:0.62±0.06,D(1)/D(0)葡萄糖:0.43±0.02)。在TMZ组中,MDA和VEGF水平及新生血管形成明显低于高渗葡萄糖组。此外,TMZ组GPx活性显著增加。
这些数据表明,不仅氧化应激的产生,而且抗氧化系统的减弱和高糖浓度均可导致腹膜内结构和功能的改变。TMZ可通过抑制腹膜内的氧化应激来维持这些改变。